Cx601

This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at

Latest news

Takeda offers €520m for stem cell firm TiGenix

CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.
CHMP backs Europe’s first allogeneic stem cell therapy

Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for
TiGenix’s Crohn's fistulas treatment wins orphan drug status

The drug - currently known as Cx601 - could potentially treat ‘complex’perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has
TiGenix cell therapy for Crohn's fistulas shows long-term benefit

In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel), an allogeneic stem cell therapy ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead
Deal Watch July 2016

Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

TiGenix appoints Dr Marie Paule Richard

In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is